Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-07-03
2010-12-07
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000, C530S327000, C530S328000, C530S317000, C435S069700, C514S009100
Reexamination Certificate
active
07846892
ABSTRACT:
The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (Aβ) protein or peptide. Anti-Aβ antibodies are selected and sequenced. In certain embodiments, synthetic Aβ binding peptides are designed and prepared, using portions of the anti-Aβ antibody sequences. The antibodies and peptides are of use for treatment of AF or for treatment of individuals at risk of developing AD. Compositions comprising anti-Aβ antibodies or Aβ binding peptides are also disclosed.
REFERENCES:
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5786324 (1998-07-01), Gray et al.
patent: 6068829 (2000-05-01), Ruoslahti et al.
patent: 6562958 (2003-05-01), Breton et al.
patent: 6703015 (2004-03-01), Solomon et al.
patent: 6743427 (2004-06-01), Schenk
patent: 2003/0223996 (2003-12-01), Ruben et al.
patent: 2004/0082762 (2004-04-01), Basi et al.
patent: 2004/0086520 (2004-05-01), Diamond
patent: 2005/0129695 (2005-06-01), Mercken et al.
patent: 2007/0021345 (2007-01-01), Gazit
patent: WO 00/72880 (2000-12-01), None
patent: WO0162801 (2001-02-01), None
patent: WO 03/056339 (2003-07-01), None
Rudikoff et al. Proc Natl Acad Sci USA, 1982; 79(6):1979-1983.
Yan et al. Science, 2000; 290(5491):523-527.
Levi et al. Proc Natl Acad Sci. USA, 1993; 90:4374-78.
Patel, Journal of Geriatric Psychiatry and Neurology, vol. 8, 81-95, 1995.
Kar et al., J. Psychiatry Neurosci., vol. 29(6), pp. 427-441, 2004.
Jacobsen et al., Neuro Rx: The Journal of the American Society for Experimental NeuroTherapeutics, vol. 2, pp. 612-626, Oct. 2005.
Lemere et al., Rejuvenation Research, vol. 9(1), pp. 77-84, 2006.
Kasim et al., Alanine-Scanning of hte 50's Loop in the Clostridium beijerinchii Flavodoxin: Evaluation of Additivity and the importance of Interactions Provided by the Main Chain in the Modulation of the Oxidation, Biochemistry, vol. 40, pp. 13548-13555, 2001.
Cai et al., Screening and characterization of human single-chain Fv antibody against Beta-amyloid peptide 40, Neuroreport, vol. 14, pp. 265-268, Feb. 10, 2003.
Vickers, “A Vaccine Against Alzheimer's Disease,” Drugs Aging, vol. 19, pp. 487-494, 2002.
Solomon, “Anti-Aggregating Antibodies, a New Approach Towards Treatment of Conformational Diseases,” Current Medicinal Chemistry, vol. 9, No. 19, pp. 1737-1749, 2002.
Schenk, “Amyloid-B immunotherapy for Alzheimer's disease: the end of the beginning,” Nature Reviews, Neuroscience, vol. 3, pp. 824-828, Oct. 2002.
Bacskai et al.; Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β in vivo by Immunotherapy; J. Neuroscience; 2002; v. 22; pp. 7873-7878.
Bard et al.; Peripherally administered antibodies against amyloid-β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease; Nat. Med.; 2000; v. 6, No. 8;pp. 916-919.
Bastianetto et al.; The Ginkgo biloba Extract (EGb 761) Protects and Rescues Hippocampal Cells Against Nitric-Oxide-Induced Toxicity: Involvement of Its Flavonoid Constituents and Protein Kinase C; J. Neurochem; 2000; v. 74, pp. 2268-2277.
Bitan et al.; Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways; Proc. Natl. Acad. Sci.; 2003; v. 100, No. 1; pp. 330-335.
Bourgeois et al.; Prophylactic Administration of a Complementarity-Determining Region Derived from a Neutralizing Monoclonal Antibody Is Effective against Respiratory Syncytial Virus Infection in BALB/c Mice; J. Virol.; 1998; v. 72, No. 1; pp. 807-810.
Brewer et al.; Optimized Survival of Hippocampal Neurons in B27-Supplemented Neurobasal™, a New Serum-free Medium Combination ; J. Neurosci. Res.; 1993; v. 35; pp. 567-576.
Calhoun et al.; Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid; Proc. Natl. Acad. Sci.; 1999; v. 96; pp. 14088-14093.
Das et al.; Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice; J. Neuroscience; 2003; v. 23; pp. 8532-8538.
Demattos et al.; Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease; Proc. Natl. Acad. Sci.; 2001; v. 98; pp. 8850-8855.
Demeester et al.; Comparison of the aggregation properties, secondary structure and apoptotoc effects of wild-type, Flemish and Dutch N-terminally truncated amyloid β peptides; Eur. J. Neurosci.; 2001; v. 13; pp. 2015-2024.
Dodart et al.; Immunization reverses memory deficits without reducing Aβ burden in Alzheimer's disease model; Nat. Neurosci.; 2002; v. 5, No. 5; pp. 452-457.
Dong et al.; Single chain Fv antibodies against neural cell adhesion molecule L1 trigger L1 functions in cultured neurons; Mol. Cell. Neurosci.; 2003; v. 22; pp. 234-247.
Fassbender et al.; Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci; 2001; v. 98; pp. 5856-5861.
Feliche et al.; Inhibition of Alzheimer's disease β-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy; FASEB J.; 2001; v. 15; pp. 1297-1299.
Frenkel et al.; N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies; J Neuroimmunol; 1998; v. 88; pp. 85-90.
Frenkel et al.; Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration; Proc Natl Acad Sci; 2000; v. 97; pp. 11455-11459.
Frenkel et al.; Filamentous phage as vector-mediated antibody delivery to the brain; Proc. Natl. Acad. Sci.; 2002; v. 99; pp. 5675-5679.
Furlan et al.; Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice; Brain; 2003; v. 126; pp. 285-291.
García et al.; Strategies for Neuroprotection Against L-Trans-2,4-Pyrrolidine Dicarboxylate-Induced Neuronal Damage During Energy Impairment In Vitro; J Neurosci Res.; 2001; v. 64; pp. 418-428.
Gaskin et al.; Human Antibodies Reactive with β-amyloid Protein in Alzheimer's disease; J. Exp. Med.; 1993; v. 177; pp. 1181 1186.
Gevorkian et al.; Identification of Autoimmune Thrombocytopenic Purpura-Related Epitopes Using Phage-Display Peptide Library; Clin. Immunol. Immunopathol.; 1998; v. 86; pp. 305-309.
Gevorkian et al.; Identification of Mimotopes of Platelet Autoantigens Associated with Autoimmune Thrombocytopenic Purpura; J. Autoimm.; 2000; v. 15; pp. 33-40.
Gevorkian et al.; Solid-phase synthesis of a peptide comprising the 605-611 disulfide loop of GP41, transmembrane glycoprotein of Human Immunodeficiency Virus Type 1 (HIV-1); Org Prep Proc Int; 1995; v. 27, No. 3; pp. 375-377.
Gouras et al.; Intraneuronal Aβ42 Accumulation in Human Brain; Am. J. Pathol.; 2000; v. 156; pp. 15-20.
Gyure et al.; Intraneuronal Aβ-Amyloid Precedes Development of Amyloid Plaques in Down Syndrome; Arch. Pathol. Lab. Med.; 2001; v. 125; pp. 489-492.
Hock et al.; Antibodies against β-Amyoid Slow Cognitive Decline in Alzheimer's Disease; 2003; Neuron; v. 3; pp. 547-554.
Janus et al.; Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease; 2000; Nature; v. 408; pp. 979-982.
Klein et al.; Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?; Trends in Neurosciences; 2001; v. 24, No. 4; pp. 219-224.
Kotilinek et al.; Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease; 2002; J. Neurosci.; v. 22; pp. 6331-6335.
Lecerf et al.; Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease; Proc. Natl. Acad. Sci.; 2001; USA; v. 98, No. 8; pp. 4764-4769.
Lemere et al.; Evidence for peripheral clearance of cerebral Aβ pr
Gevorgyan Gohar
Manucharyan Karen
Ballard Kimberly A.
Faegre & Benson LLP
Kemmerer Elizabeth C.
Primex Clinical Laboratories, Inc.
LandOfFree
Compositions and methods for Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for Alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4222763